Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 637-640

  Dorsch, Oliver ^a  

^a KfH Kuratorium für Dialyse und Nierentransplantation E V   (Germany)

Author keywords

Calcimimetics; Cinacalcet; Hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE;

ABSENCE OF SIDE EFFECTS; ADULT; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; CORONARY STENT; DISEASE RESISTANCE; DRUG DOSE TITRATION; DRUG USE; FEMALE; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARATHYROIDECTOMY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SYMPTOM; TRANSLUMINAL CORONARY ANGIOPLASTY;

FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; TIME FACTORS;

EID: 33846674589     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl547     Document Type: Article

References (15)

1. Tominaga Y. Management of renal hyperparathyroidism. Biomed Pharmacother 2000; 54 [Suppl 1]: 25-31
2. Hoerl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19 [Suppl 5]: V2-V8
3. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
4. Drüeke TB. Calcimimetics versus vitamin D: What are their relative roles? Blood Purif 2004; 22: 38-43
5. Tominaga Y, Katayama A, Sato T et al. Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients. Nephrol Hypertens 2003; 18 [Suppl 3]: 65-70
6. Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 87-97
7. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 939-942
8. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
9. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondaryhyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
10. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis 2003; 42 [Suppl 3]: S1-S201
11. Fluck R, Taal M, MacIntyre C, Symes F. Cinacalcet in severe hyperparathyroidism. Poster presented at XLIII ERA-EDTA Congress, Glasgow, UK, July 15-18, 2006 (SP343)
12. Dattolo P, Michelassi S, Ferro G et al. Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. Poster presented at XLIII ERA-EDTA Congress, Glasgow, UK, July 15-18, 2006 (SP344)
13. Moe SM, Goodman WG, Cunningham J et al. Cinacalcet sustains long-term control of secondary hyperparathyroidism (HPT). Poster presented at 36th Annual Meeting of the American Society for Neurochemistry, Madison, Wisconsin, USA, 25-29 June 2005 (F-P0755)
14. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Eng J Med 2004; 350: 1516-1525
15. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet. Nephrol Dial Transplant 2005; 20: 2186-2193